 Upadacitinib (Rinvoq)is a Janus kinase (JAK) inhibitor being investigated to treat rheumatoid arthritis, Crohn disease, ulcerative colitis, atopic dermatitis, psoriatic arthritis, axial SpA giant cell arteritis, and Takayasu arteritis.

 The recommended dosage of Rinvoq is 15 mg once daily.

: Extended-release tablets 15 mg and 30 mg.

Adverse reactions (≥ 1%) were upper respiratory tract infections, herpes zoster, herpes simplex, bronchitis, nausea, cough, pyrexia, and acne.

: JAKs are intracellular enzymes that transmit signals arising from cytokine or growth factor-receptor interactions on the cellular membrane to influence cellular processes of hematopoiesis and immune cell function.

Microsoft Word - master-uspi-upadacitinib (rxabbvie.com)

News

Specialty Pharmacy

® Pharmacy Technician Clinical Role section is a comprehensive resource for clinical news and expert insights on issues pertaining to specialty pharmacists.

Dermatology

® Dermatology Resource Center is a comprehensive resource for clinical news and expert insights on the treatment of skin disorders, including psoriasis, atopic dermatitis, eczema, and acne.

Rheumatoid Arthritis

Digestive Health

® Digestive Health Resource Center is a comprehensive resource for clinical news and expert insights on issues related to health of the digestive system, including Crohn disease, inflammatory bowel disease, irritable bowel syndrome, and ulcerative colitis.

Upadacitinib (Rinvoq) is a Janus kinase (JAK) inhibitor being investigated to treat rheumatoid arthritis, Crohn disease, ulcerative colitis, atopic dermatitis, psoriatic arthritis, axial SpA giant cell arteritis, and Takayasu arteritis

Daily Medication Pearl: Upadacitinib (Rinvoq)